Hims & Hers closed Q2 2025 with $544.8M in revenue up 73% year-over-year net income of $42.5M, and 2.44M subscribers. The company reaffirmed its full-year outlook.

Hims & Hers enters Canadian market with a digital weight loss program leveraging generic semaglutide, signaling increased competition and accessibility in the growing GLP-1 and obesity treatment sector.

Novo Nordisk has ended its collaboration with Hims & Hers, citing concerns over compounded versions of Wegovy®. The decision follows scrutiny around patient safety and regulatory compliance in the telehealth weight loss space.